Alpha 2.0
Login Register
» Articles » PMID: 1510422

Therapy of Experimental Murine Brucellosis with Streptomycin, Co-trimoxazole, Ciprofloxacin, Ofloxacin, Pefloxacin, Doxycycline, and Rifampin

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 1992 May 1
PMID 1510422
Citations 9
Authors
B SHASHA
R Lang
E Rubinstein
Affiliations
Soon will be listed here.
Abstract

Mice infected with Brucella melitensis were treated with streptomycin, co-trimoxazole, ciprofloxacin, doxycycline, and rifampin intraperitoneally and with ciprofloxacin, ofloxacin, pefloxacin, doxycycline, and rifampin orally for 14 to 21 days. Doxycycline- and rifampin-treated animals (either route) demonstrated a cure rate significantly better than that of controls. Longer therapy periods were associated with a significantly better outcome. Therapy failure was observed in all mice treated with ciprofloxacin, ofloxacin, and pefloxacin administered orally as well as in mice treated intraperitoneally with ciprofloxacin. Our findings demonstrate that treatment of experimental brucellosis in mice with doxycycline and rifampin yields therapeutic results that are superior to those yielded by treatment with quinolones.

Citing Articles

Re-evaluation of FDA-approved antibiotics with increased diagnostic accuracy for assessment of antimicrobial resistance.

Heithoff D, Barnes V L, Mahan S, Fried J, Fitzgibbons L, House J Cell Rep Med. 2023; 4(5):101023.

PMID: 37116500 PMC: 10213814. DOI: 10.1016/j.xcrm.2023.101023.

Anti-Brucella activity of Caryopteris mongolica Bunge root extract against Brucella melitensis infection in mice.

N T, B N, O O, D D, J B BMC Complement Altern Med. 2018; 18(1):144.

PMID: 29724202 PMC: 5934838. DOI: 10.1186/s12906-018-2220-y.

Hydrophobic gentamicin-loaded nanoparticles are effective against Brucella melitensis infection in mice.

Imbuluzqueta E, Gamazo C, Lana H, Campanero M, Salas D, Gil A Antimicrob Agents Chemother. 2013; 57(7):3326-33.

PMID: 23650167 PMC: 3697350. DOI: 10.1128/AAC.00378-13.

Laboratory animal models for brucellosis research.

Silva T, Costa E, Paixao T, Tsolis R, Santos R J Biomed Biotechnol. 2011; 2011:518323.

PMID: 21403904 PMC: 3043301. DOI: 10.1155/2011/518323.

In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model.

Wolff M, Joly-Guillou M, Farinotti R, Carbon C Antimicrob Agents Chemother. 1999; 43(6):1406-11.

PMID: 10348761 PMC: 89287. DOI: 10.1128/AAC.43.6.1406.

References
1.
Hall W . Modern chemotherapy for brucellosis in humans. Rev Infect Dis. 1990; 12(6):1060-99. DOI: 10.1093/clinids/12.6.1060. View
2.
Fountain M, Weiss S, Fountain A, Shen A, Lenk R . Treatment of Brucella canis and Brucella abortus in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides. J Infect Dis. 1985; 152(3):529-35. DOI: 10.1093/infdis/152.3.529. View
3.
Philippon A, Kazmierczak A, Nevot P . [Treatment of brucellosis associated with corynebacterium parvum infection in mice with antibiotics (tetracycline, ampicillin, trimethoprim-sulfamethoxazole)]. Ann Inst Pasteur (Paris). 1972; 123(3):349-62. View
4.
BRAUDE A, SPINK W . The action of aureomycin and other chemotherapeutic agents in experimental brucellosis. J Immunol. 1950; 65(2):185-99. View
5.
Shaffer J, Kucera C, SPINK W . Evaluation of prolonged antibiotic therapy in mice with chronic Brucella infection due to Brucella melitensis. J Immunol. 1953; 70(1):31-8. View